Immix Biopharma, Inc.
IMMX
Rank in Stocks
#11177
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to... Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Share Price
$8.07
Last synced: 2026-11-12
Market Cap
$597.89M
Change (1 day)
-6.81%
Change (1 year)
123.55%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Immix Biopharma, Inc. (IMMX)
Category
Healthcare
EPS for Immix Biopharma, Inc. (IMMX)
EPS as of June 2026 TTM: $-0.88
According to Immix Biopharma, Inc.'s latest financial reports, its current EPS (TTM) is $-0.88. At the end of 2025 the company had an EPS of $-0.89, a decrease compared to its 2024 EPS of $-0.76.
EPS history for Immix Biopharma, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.88 | -1.12% |
| 2025 | $-0.89 | 17.11% |
| 2024 | $-0.76 | -14.61% |
| 2023 | $-0.89 | 50.85% |
| 2022 | $-0.59 | -91.11% |
| 2021 | $-6.64 | 4,326.67% |
| 2020 | $-0.15 | -48.28% |
| 2019 | $-0.29 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,879.55% |
US
|
|
| $-7.07 | 703.41% |
US
|
|
| $-5.29 | 501.14% |
AU
|
|
| $12.88 | -1,563.65% |
BE
|
|
| $21.56 | -2,550.00% |
NL
|
Questions about Immix Biopharma, Inc.'s earnings per share (EPS)
What is Immix Biopharma, Inc.'s earnings per share (EPS)?
Immix Biopharma, Inc.'s earnings per share (EPS) over the last twelve months is $-0.88, as of Jun 2026.
What was Immix Biopharma, Inc.'s earnings per share (EPS) in 2025?
In 2025, Immix Biopharma, Inc.'s earnings per share (EPS) was $-0.89, compared with $-0.76 in 2024.
How has Immix Biopharma, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Immix Biopharma, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.15) and lowest in 2021 ($-6.64).
How does Immix Biopharma, Inc.'s earnings per share (EPS) compare with similar companies?
Immix Biopharma, Inc.'s earnings per share (EPS) ($-0.88) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.